Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Growth Opportunities

Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Growth Opportunities

Emerging Pharmaceuticals and Highly Potent Complex Molecules Creating Future Growth Potential

RELEASE DATE
13-Sep-2021
REGION
North America
Research Code: PBE8-01-00-00-00
SKU: HC03449-NA-MT_25771
$4,950.00
In stock
SKU
HC03449-NA-MT_25771
$4,950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global small molecule contract development and manufacturing organization (CDMO) industry. It highlights key growth opportunities for small molecule CDMOs based on the main evolution in their business models and strategic approaches as well as those of pharmaceutical sponsors. The study segments the market into two categories based on product type: Active pharmaceutical ingredients (API) manufacturing (API/drug substance) and finished dosage form (FDF) manufacturing (FDF/drug product). API is further segmented into innovator and generic APIs, while FDF is segmented into oral, semi-solid/liquid, and injectable forms. The market forecasts in this report are for 2020–2026, capturing key market developments such as capacity expansions, mergers, acquisitions, and expanding service offerings that are set to affect the overall small molecule CDMO market growth.

Other discussions in the study include:
• The impact of strategic imperatives on the industry
• Growth drivers and restraints
• Comprehensive insights on the competitive landscape
• Revenue share estimates of top market participants
• Strategic analysis of market developments in service offerings and business models
• Growth opportunities for small molecule CDMOs

Author: Surbhi Gupta

Table of Contents

Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top Three Strategic Imperatives on the Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Scope of Analysis

Market Segmentation by Product Type

Market Segmentation by Service Type

Key Competitors

Key Growth Metrics

Growth Drivers for the Small Molecule CDMO Market

Growth Restraints for the Small Molecule CDMO Market

Forecast Framework—Market Sizing

Forecast Methodology

Forecast Assumptions and Considerations

Revenue Forecast

Revenue Forecast Analysis

Revenue Forecast by Product Type

Revenue Forecast Analysis by Product Type

Revenue Forecast by Region

Revenue Forecast Analysis by Region

Major Reshoring Initiatives for Pharmaceutical Manufacturing

Revenue Split by Service Type

Revenue Split Analysis by Service Type

Competitive Environment

Market Share, Total Pharmaceutical CDMO Market

Small Molecule Market Outlook—Key Segment Share

Comparison between Small Molecules and Biologics Approvals

Expanding CDMO Value Chain—Comprehensive End-to-end Offering for Small Molecules and Biologics

CDMO Business Model Evolution—Transactional to Strategic Partnerships

Key Growth Trends Shaping the Small Molecule CDMO Industry

Key Consolidation and Expansion Steps in the Small Molecule CDMO Industry

Key Expansion Initiatives by Small Molecule CDMOs

Key Growth Metrics, Small Molecule CDMO Market—API

Revenue Forecast, Small Molecule CDMO Market—API

Revenue Forecast by Product Type, Small Molecule CDMO Market—API

Revenue Forecast Analysis by Product Type, Small Molecule CDMO Market—API

Key Growth Metrics, Small Molecule CDMO Market—FDF

Revenue Forecast, Small Molecule CDMO Market—FDF

Revenue Forecast by Product Type, Small Molecule CDMO Market—FDF

Revenue Forecast Analysis by Product Type, Small Molecule CDMO Market—FDF

Revenue Forecast Analysis by Product Type, Small Molecule CDMO Market—FDF (continued)

Growth Opportunity 1—Capacity Expansion in the US and Europe for Reshoring and Near-shoring Manufacturing

Growth Opportunity 1—Capacity Expansion in the US and Europe for Reshoring and Near-shoring Manufacturing (continued)

Growth Opportunity 2—Phase-appropriate Manufacturing Services for High-potency Drugs

Growth Opportunity 2—Phase-appropriate Manufacturing Services (continued)

Growth Opportunity 2—Phase-appropriate Manufacturing Services for High-potency Drugs (continued)

Growth Opportunity 3—Focus on Small/Emerging Biopharmaceutical Companies to Develop Innovative Small Molecules

Growth Opportunity 3—Focus on Small/Emerging Biopharmaceutical Companies to Develop Innovative Small Molecules (continued)

Growth Opportunity 4—Integrated Drug–Device Combination Products Services for New and Existing Drugs

Growth Opportunity 4—Integrated Drug–Device Combination Products Services for New and Existing Drugs (continued)

Your Next Steps

Why Frost, Why Now?

List of Exhibits

List of Exhibits (continued)

Legal Disclaimer

This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global small molecule contract development and manufacturing organization (CDMO) industry. It highlights key growth opportunities for small molecule CDMOs based on the main evolution in their business models and strategic approaches as well as those of pharmaceutical sponsors. The study segments the market into two categories based on product type: Active pharmaceutical ingredients (API) manufacturing (API/drug substance) and finished dosage form (FDF) manufacturing (FDF/drug product). API is further segmented into innovator and generic APIs, while FDF is segmented into oral, semi-solid/liquid, and injectable forms. The market forecasts in this report are for 2020–2026, capturing key market developments such as capacity expansions, mergers, acquisitions, and expanding service offerings that are set to affect the overall small molecule CDMO market growth. Other discussions in the study include: • The impact of strategic imperatives on the industry • Growth drivers and restraints • Comprehensive insights on the competitive landscape • Revenue share estimates of top market participants • Strategic analysis of market developments in service offerings and business models • Growth opportunities for small molecule CDMOs Author: Surbhi Gupta
More Information
No Index No
Podcast No
Predecessor MEF6
Author Surbhi Gupta
Industries Healthcare
WIP Number PBE8-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9825-B1,9A06-B1,9571-B1,99BF-B1,99C0-B1,99C1-B1,99CB-B1,9568-B1,9611-B1